首页> 外文会议>Microbial engineering >REPLACING ANIMAL-BASED HYDROLYSATES IN BIOPHARMACEUTICAL PROCESSES WITH ANIMALFREE AND CHEMICALLY DEFINED ALTERNATIVES TO REDUCE REGULATORY CONCERNS
【24h】

REPLACING ANIMAL-BASED HYDROLYSATES IN BIOPHARMACEUTICAL PROCESSES WITH ANIMALFREE AND CHEMICALLY DEFINED ALTERNATIVES TO REDUCE REGULATORY CONCERNS

机译:用动物性的和化学定义的替代品代替生物制药过程中基于动物的水解物,以减少监管问题

获取原文
获取原文并翻译 | 示例

摘要

Many biopharmaceutical products are routinely manufactured with biological systems (i.e. mammalian and/or microbial cell lines) and consequently, concerns regarding the product's quality, efficacy and safety are raised. Due to the complexity of these "biological systems," many regulatory agencies intensely scrutinize these products prior to approving them for human usage. When working with biological systems, it is presumed that the cultivating medium plays a significant role in product manufacturing; specifically, in terms of product efficacy, quality and titer. To achieve cost efficiency and titer requirements in commercial scale processes, protein hydrolysates are classically used complex sources of nitrogen to support cellular growth and productivity. Over the past century, the main types of protein hydrolysates are typically made from animal-based materials such as milk (e.g. casein), muscle tissue, and organ meats (i.e. heart, brain, spleen). These animal-based hydrolysates have been shown to play a crucial role in vaccine production and food fermentations where high-density, productive cultures are required to achieve the final output. However, with incidences of bovine spongiform encephalopathy occurring over the past decade, regulatory bodies have become more concerned with the use of animal-based materials in fear of transmitting animal diseases to humans. To address these concerns, many hydrolysate suppliers are starting to produce vegetable-based hydrolysates (i.e. soy, wheat, corn, pea, etc.) and yeast extracts. In addition to these vegetable sourced hydrolysates, a handful of companies are developing chemically-defined media and/or supplements to completely remove hydrolysates from media formulations. As a leading, global manufacturer of complex nitrogen sources, Kerry offers a multitude of various protein hydrolysates, yeast extracts and chemically defined media to meet the needs and desires of numerous markets.
机译:许多生物制药产品通常是用生物系统(即哺乳动物和/或微生物细胞系)制造的,因此,引起了人们对产品质量,功效和安全性的担忧。由于这些“生物系统”的复杂性,许多监管机构在批准这些产品供人类使用之前会仔细检查这些产品。假定在生物系统中工作时,培养介质在产品制造中起着重要作用;特别是在产品功效,质量和滴度方面。为了在商业规模的过程中达到成本效率和效价要求,蛋白质水解产物是传统上使用的复杂氮源,以支持细胞的生长和生产力。在过去的一个世纪中,蛋白质水解产物的主要类型通常由基于动物的材料制成,例如牛奶(例如酪蛋白),肌肉组织和器官肉(即心脏,大脑,脾脏)。这些基于动物的水解产物已显示在疫苗生产和食品发酵中起着至关重要的作用,在疫苗生产和食品发酵中,需要高密度的生产性培养才能达到最终产量。然而,由于过去十年中发生了牛海绵状脑病的发生,监管机构更加担心使用基于动物的材料,以免将动物疾病传播给人类。为了解决这些问题,许多水解产物供应商开始生产基于蔬菜的水解产物(即大豆,小麦,玉米,豌豆等)和酵母提取物。除了这些植物来源的水解产物外,少数公司还在开发化学成分确定的培养基和/或补品,以从培养基配方中完全去除水解产物。作为复杂氮源的全球领先制造商,凯瑞提供多种蛋白质水解产物,酵母提取物和化学成分确定的培养基,以满足众多市场的需求。

著录项

  • 来源
    《Microbial engineering》|2018年|50-50|共1页
  • 会议地点 Santa Fe(US)
  • 作者

    Floyd L. Inman;

  • 作者单位

    Kerry, USA;

  • 会议组织
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

  • 入库时间 2022-08-26 14:31:43

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号